Navigation Links
Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
Date:2/2/2009

PRINCETON, N.J., Feb. 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it will receive a milestone payment of $1 million from its partner, MedImmune, LLC for the allowance of an Investigational New Drug (IND) application for MEDI-546, a fully human antibody that targets a component of the type 1 interferon pathway. MEDI-546 will be studied in patients with scleroderma, a chronic autoimmune disease characterized by hardening and thickening of the skin and other organs.

"This IND application marks the second antibody targeting the interferon inflammatory pathway that MedImmune has supported for advancement into the clinic using our UltiMAb(R) technology," said Howard H. Pien, Chairman and CEO of Medarex.

In November 2004, MedImmune entered into collaboration with Medarex to focus on two specific antibodies, MDX-1103 (now known as MEDI-545) and MDX-1333 (now known as MEDI-546). Under the terms of the agreement, MedImmune is responsible for all ongoing clinical development activities. Prior to the beginning of pivotal studies, Medarex may elect to co-develop the products in return for the opportunity to co-promote and to receive a share of the commercial profits in the United States. In all other cases, Medarex will be entitled to receive milestone payments and royalties.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates f
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Medarex Reviews Recent Highlights and Outlook for 2009
2. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
3. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
4. Medarex Announces 2008 First Quarter Financial Results
5. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
6. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
7. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
8. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
9. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
10. Medarex to Present at the JPMorgan Small/Mid Cap Conference
11. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 2Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 3Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 4Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 5Ascension Orthopedics Hires Key Senior Executives 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Akorn Inc Announces Third Quarter 2009 Earnings Release and Conference Call Information 60113 1Reportlinker Adds Bioinformatics and Computational Biology 3A Bottlenecks and Options 14598 1Reportlinker Adds Bioinformatics and Computational Biology 3A Bottlenecks and Options 14598 2Reportlinker Adds Bioinformatics and Computational Biology 3A Bottlenecks and Options 14598 3Reportlinker Adds Bioinformatics and Computational Biology 3A Bottlenecks and Options 14598 4Reportlinker Adds Bioinformatics and Computational Biology 3A Bottlenecks and Options 14598 5Reportlinker Adds Bioinformatics and Computational Biology 3A Bottlenecks and Options 14598 6Reportlinker Adds Bioinformatics and Computational Biology 3A Bottlenecks and Options 14598 7Reportlinker Adds Bioinformatics and Computational Biology 3A Bottlenecks and Options 14598 8Reportlinker Adds Bioinformatics and Computational Biology 3A Bottlenecks and Options 14598 9Reportlinker Adds Bioinformatics and Computational Biology 3A Bottlenecks and Options 14598 10Reportlinker Adds Bioinformatics and Computational Biology 3A Bottlenecks and Options 14598 11Medivation to Host Conference Call at 8 3A30 a m Eastern Time Tomorrow to Discuss Partnering Plans for MDV3100 14596 1